Avidity Partners Management LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Avidity Partners Management LP reported 55 stock positions worth $498.8 million. Its top holding was CG Oncology (CGON) at 7.8% of the portfolio, followed by Boston Scientific (BSX, 6.9%) and Natera (NTRA, 6.8%). Compared with Q1 2025, it opened 17 new positions, sold out of 25, added to 18 and reduced 13. The biggest buy was a new position in Hinge Health Class A (HNGE) and the biggest sale Unitedhealth (UNH, shares −37%).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $498.8M (Q2 2025)
- SEC Filing
- 0001791827-25-000007 ↗ filed Aug 14, 2025
Holdings Value
Holdings 55 stocks · $498.8M
| CGON CG Oncology Inc. | 7.82% | 1,499,942 | $39.0M | Add +52.9% |
| BSX Boston Scientific Corp. | 6.93% | 321,800 | $34.6M | Reduce -4.2% |
| NTRA Natera Inc. | 6.75% | 199,300 | $33.7M | Add +67.2% |
| DNTH Dianthus Therapeutics Inc. | 6.51% | 1,742,902 | $32.5M | Add +1.3% |
| EXAS Exact Sciences Corp. | 3.78% | 355,000 | $18.9M | Add +0.6% |
| THC Tenet Healthcare Corp. | 3.74% | 106,000 | $18.7M | Add +47.2% |
| DXCM Dexcom Inc. | 3.68% | 210,500 | $18.4M | Add +16.9% |
| DHR Danaher Corp. | 3.55% | 89,700 | $17.7M | Add +101.6% |
| HNGE Hinge Health Inc. Class A | 3.34% | 322,344 | $16.7M | New |
| ISRG Intuitive Surgical Inc. | 2.95% | 27,100 | $14.7M | New |
| GMAB Genmab A/S -SP ADR | 2.69% | 650,000 | $13.4M | New |
| RGEN Repligen Corp. | 2.66% | 106,500 | $13.2M | New |
| TMO Thermo Fisher Scientific Inc. | 2.41% | 29,600 | $12.0M | Add +91.0% |
| TEVA Teva Pharmaceutical-SP ADR | 2.32% | 689,500 | $11.6M | Add +43.4% |
| JBIO Jade Biosciences Inc. | 2.26% | 1,127,186 | $11.3M | New |
| PHAT Phathom Pharmaceuticals Inc. | 2.05% | 1,064,500 | $10.2M | Add +33.1% |
| UNH Unitedhealth Group Inc. | 2.00% | 32,000 | $10.0M | Reduce -36.6% |
| MCK McKesson Corp. | 1.98% | 13,500 | $9.9M | New |
| AXSM Axsome Therapeutics Inc. | 1.98% | 94,500 | $9.9M | Add +22.7% |
| COR Cencora Inc. | 1.97% | 32,800 | $9.8M | Reduce -16.5% |
| HQY Healthequity Inc. | 1.93% | 92,000 | $9.6M | Add +17.9% |
| EHC Encompass Health Corp. | 1.82% | 74,000 | $9.1M | New |
| RVMD Revolution Medicines Inc. | 1.69% | 228,600 | $8.4M | Add +7.3% |
| AKRO Akero Therapeutics Inc. | 1.43% | 134,000 | $7.2M | Add +135.1% |
| OMDA Omada Health Inc. | 1.43% | 390,600 | $7.1M | New |
| BEAM Beam Therapeutics Inc. | 1.40% | 409,400 | $7.0M | Reduce -42.3% |
| HUM Humana Inc. | 1.35% | 27,600 | $6.7M | Reduce -65.9% |
| CATX Perspective Therapeutics Inc. | 1.28% | 1,858,596 | $6.4M | Reduce -15.4% |
| OGN Organon & Co. | 1.24% | 640,000 | $6.2M | Add +19.6% |
| BBIO Bridgebio Pharma Inc. | 1.21% | 140,000 | $6.0M | Add +86.7% |
| INSM Insmed Inc. | 1.19% | 59,000 | $5.9M | Reduce -44.9% |
| MDGL Madrigal Pharmaceuticals Inc. | 1.15% | 19,000 | $5.8M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 1.12% | 154,000 | $5.6M | Reduce -52.2% |
| CNTX Context Therapeutics Inc. | 0.98% | 7,477,255 | $4.9M | Add +0.0% |
| ORKA Oruka Therapeutics Inc. | 0.79% | 352,124 | $3.9M | No change |
| IMUX Immunic Inc. | 0.79% | 5,615,811 | $3.9M | Add +26.1% |
| ARQT Arcutis Biotherapeutics Inc. | 0.75% | 268,000 | $3.8M | New |
| DOCS Doximity Inc. Class A | 0.74% | 60,000 | $3.7M | Reduce -51.0% |
| XENE Xenon Pharmaceuticals Inc. | 0.68% | 107,891 | $3.4M | Reduce -52.9% |
| VRNA Verona Pharma Ltd. | 0.64% | 33,800 | $3.2M | New |
| QURE Uniqure NV | 0.58% | 207,000 | $2.9M | Reduce -38.4% |
| APGE Apogee Therapeutics Inc. | 0.57% | 65,000 | $2.8M | New |
| SLNO Soleno Therapeutics Inc. | 0.54% | 32,000 | $2.7M | No change |
| CAH Cardinal Health Inc. | 0.51% | 15,000 | $2.5M | New |
| SPRY Ars Pharmaceuticals Inc. | 0.49% | 140,000 | $2.4M | New |
| KZR Kezar Life Sciences Inc. | 0.46% | 502,600 | $2.3M | No change |
| NTLA Intellia Therapeutics Inc. | 0.44% | 232,000 | $2.2M | New |
| MLTX Moonlake Immunotherapeutics | 0.37% | 39,000 | $1.8M | New |
| ARVN Arvinas Inc. | 0.36% | 243,162 | $1.8M | Reduce -41.1% |
| SNDX Syndax Pharmaceuticals Inc. | 0.28% | 150,000 | $1.4M | Reduce -83.8% |
| SCYX Scynexis Inc. | 0.17% | 1,228,910 | $829K | No change |
| KPTI Karyopharm Therapeutics Inc. | 0.12% | 134,566 | $580K | No change |
| ALT Altimmune Inc. | 0.08% | 105,000 | $406K | New |
| ELVN Enliven Therapeutics Inc. | 0.05% | 11,300 | $227K | No change |
| REVIVA PHARMACEUTCLS HLDGS I | 0.01% | 138,000 | $53K | No change |
Options reported separately and not counted above: SNDX calls ($3.2M).
Portfolio Sells Q1 2025 → Q2 2025
| UNH Unitedhealth Group Inc. | Reduce -36.6% | 2.00% | −3.45 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −3.32 |
| HUM Humana Inc. | Reduce -65.9% | 1.35% | −3.07 |
| GKOS Glaukos Corp. | Sold out | 0.00% | −2.72 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -83.8% | 0.28% | −2.06 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −2.05 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −1.95 |
| XBI SS SPDR S&P Biotech ETF | Sold out | 0.00% | −1.57 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −1.57 |
| AVTR Avantor Inc. | Sold out | 0.00% | −1.51 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −1.50 |
| BEAM Beam Therapeutics Inc. | Reduce -42.3% | 1.40% | −1.46 |
| JANX Janux Therapeutics Inc. | Sold out | 0.00% | −1.44 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -52.2% | 1.12% | −1.28 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −1.25 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −1.07 |
| BRKR Bruker Corp. | Sold out | 0.00% | −0.99 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -52.9% | 0.68% | −0.91 |
| DOCS Doximity Inc. Class A | Reduce -51.0% | 0.74% | −0.73 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −0.72 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.58 |
| RPRX Royalty Pharma PLC Class A | Sold out | 0.00% | −0.56 |
| INSM Insmed Inc. | Reduce -44.9% | 1.19% | −0.49 |
| CAPR Capricor Therapeutics Inc. | Sold out | 0.00% | −0.47 |
| LXEO Lexeo Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −0.45 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.38 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −0.37 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.37 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.29 |
| COR Cencora Inc. | Reduce -16.5% | 1.97% | −0.28 |
| AGL Agilon Health Inc. | Sold out | 0.00% | −0.27 |
| ARVN Arvinas Inc. | Reduce -41.1% | 0.36% | −0.24 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −0.18 |
| QURE Uniqure NV | Reduce -38.4% | 0.58% | −0.16 |
| BSX Boston Scientific Corp. | Reduce -4.2% | 6.93% | −0.06 |
| HYPR Hyperfine Inc. | Sold out | 0.00% | −0.03 |
| CATX Perspective Therapeutics Inc. | Reduce -15.4% | 1.28% | +0.32 |
Portfolio Buys Q1 2025 → Q2 2025
| HNGE Hinge Health Inc. Class A | New | 3.34% | +3.34 |
| NTRA Natera Inc. | Add +67.2% | 6.75% | +3.27 |
| ISRG Intuitive Surgical Inc. | New | 2.95% | +2.95 |
| CGON CG Oncology Inc. | Add +52.9% | 7.82% | +2.86 |
| GMAB Genmab A/S -SP ADR | New | 2.69% | +2.69 |
| RGEN Repligen Corp. | New | 2.66% | +2.66 |
| JBIO Jade Biosciences Inc. | New | 2.26% | +2.26 |
| MCK McKesson Corp. | New | 1.98% | +1.98 |
| EHC Encompass Health Corp. | New | 1.82% | +1.82 |
| THC Tenet Healthcare Corp. | Add +47.2% | 3.74% | +1.74 |
| DHR Danaher Corp. | Add +101.6% | 3.55% | +1.67 |
| OMDA Omada Health Inc. | New | 1.43% | +1.43 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 1.15% | +1.15 |
| DXCM Dexcom Inc. | Add +16.9% | 3.68% | +1.15 |
| PHAT Phathom Pharmaceuticals Inc. | Add +33.1% | 2.05% | +1.01 |
| AKRO Akero Therapeutics Inc. | Add +135.1% | 1.43% | +0.96 |
| TMO Thermo Fisher Scientific Inc. | Add +91.0% | 2.41% | +0.82 |
| TEVA Teva Pharmaceutical-SP ADR | Add +43.4% | 2.32% | +0.79 |
| ARQT Arcutis Biotherapeutics Inc. | New | 0.75% | +0.75 |
| BBIO Bridgebio Pharma Inc. | Add +86.7% | 1.21% | +0.68 |
| VRNA Verona Pharma Ltd. | New | 0.64% | +0.64 |
| EXAS Exact Sciences Corp. | Add +0.6% | 3.78% | +0.63 |
| APGE Apogee Therapeutics Inc. | New | 0.57% | +0.57 |
| HQY Healthequity Inc. | Add +17.9% | 1.93% | +0.51 |
| CAH Cardinal Health Inc. | New | 0.51% | +0.51 |
| SPRY Ars Pharmaceuticals Inc. | New | 0.49% | +0.49 |
| NTLA Intellia Therapeutics Inc. | New | 0.44% | +0.44 |
| MLTX Moonlake Immunotherapeutics | New | 0.37% | +0.37 |
| RVMD Revolution Medicines Inc. | Add +7.3% | 1.69% | +0.13 |
| AXSM Axsome Therapeutics Inc. | Add +22.7% | 1.98% | +0.13 |
| ALT Altimmune Inc. | New | 0.08% | +0.08 |
| DNTH Dianthus Therapeutics Inc. | Add +1.3% | 6.51% | +0.07 |
| CNTX Context Therapeutics Inc. | Add +0.0% | 0.98% | +0.04 |
| IMUX Immunic Inc. | Add +26.1% | 0.79% | −0.22 |
| OGN Organon & Co. | Add +19.6% | 1.24% | −0.40 |
Options Activity Q1 2025 → Q2 2025
| HUM Humana Inc. | call | Sold out | 80,000 | $21.2Mbefore exit |
| GMAB Genmab A/S -SP ADR | call | Sold out | 433,100 | $8.5Mbefore exit |
| ARVN Arvinas Inc. | call | Sold out | 750,000 | $5.3Mbefore exit |
| SNDX Syndax Pharmaceuticals Inc. | call | Reduce -15.0% | 340,000 | $3.2M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |